To evaluate the literature characterizing the mechanism of action, pharmacokinetics, pharmacodynamics, and therapeutic efficacy of plerixafor for hematopoietic stem cell (HSC) mobilization for autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma.
DATA SOURCES
A PubMed search (1966-September 2009) was conducted using the key words plerixafor and AMD3100. Manufacturer's prescribing information was also used.
STUDY SELECTION AND DATA EXTRACTION
English-language articles were selected and data were extracted with a focus on clinical studies of HSC mobilization in patients with NHL or multiple myeloma.
DATA SYNTHESIS
Plerixafor exerts its effect by reversibly blocking the ability of HSC to bind to the bone marrow matrix. When used with granulocyte colony-stimulating factor (G-CSF), plerixafor helps increase the number of HSCs in the peripheral blood, where they can be collected for use in autologous transplantation. In clinical studies, plerixafor was rapidly absorbed after subcutaneous injection, reaching a maximum plasma concentration at approximately 0.5 hours. Plerixafor is renally excreted as the parent drug, with an elimination half-life ranging from 3 to 5 hours. Plerixafor increases circulating CD34+ cells in the peripheral blood, with a peak effect about 6–9 hours after subcutaneous administration. An approximate 2- to 3-fold increase in the CD34+ cell count is seen by the first dose of plerixafor after 4 consecutive days of G-CSF treatment. In 2 Phase 3 studies in patients with NHL or multiple myeloma, addition of plerixafor to G-CSF resulted in a higher CD34+ cell collection with fewer apheresis days, but failed to show better graft durability or overall patient survival for up to 12 months of follow-up.
CONCLUSIONS
Clinical trials have demonstrated that the addition of plerixafor to G-CSF was beneficial for HSC mobilization to peripheral blood for collection and subsequent transplantation in patients with NHL or multiple myeloma. Further studies should assess the benefit of the additive use of plerixafor on clinical outcomes.
. BensingerWI.Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia2009;23:442–8. DOI 10.1038/Leu.2008.396.
2.
. HosingCSalibaRMOkorojiGJHigh-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients <65 years of age. Ann Oncol2008;19:1166–71. DOI 10.1093/annonc/mdm608.
3.
. DevineSMFlomenbergNVesoleDHRapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol2004;22:1095–102. DOI 10.1200/JCO.2004.07.131.
4.
. RosenbeckLLSrivastavaSKielPJ.Plerixafor with granulocyte colony-stimulating factor for stem cell mobilization. Ann Pharmacother2010; 44:XX–XX. Epub XXX. DOI 10.1345/aph.1M289.
5.
. DiPersioJFUyGLYasothanUKirkpatrickP.Plerixafor. Nat Rev Drug Discov2009;8:105–6. DOI 10.1038/nrd2819.
6.
. PusicIJiangSYLanduaSImpact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant2008;14:1045–56.
. UyGLRettigMPCashenAF.Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther2008;8:1797–804. DOI 10.1517/14712598.8.11.1797.
9.
. WagstaffAJ.Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma. Drugs2009;69:319–26. DOI 10.2165/00003495-200969030-23107.
10.
. De ClercqE.The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol2009;77:1655–64.
11.
. HendrixCWFlexnerCMacFarlandRTPharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother2000;44:1667–73.
12.
. StewartDASmithCMacFarlandRCalandraG.Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant2009;15: 39–46.
13.
. DouglasSSmithCMacFarlandRAMD3100 with G-CSF for autologous peripheral blood progenitor cell (PBPC) mobilization in non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM): mobilization, engraftment, and pharmacokinetics (PK) [48th ASH Annual Meeting abstract]. Blood2006;108:3383.
14.
. LackNAGreenBDaleDCA pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther2005;77:427–36. DOI 10.1016/j.clpt.2004.12.268.
15.
. HubelKLilesWCBroxmeyerHELeukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther2004;1:165–72. DOI 10.3816/SCT.2004.n.008.
16.
. De ClercqE.The bicyclam AMD 3100 story. Nat Rev Drug Discov2003;2:581–7. DOI 10.1038/nrd1134.
17.
. LilesWCBroxmeyerHERodgerEMobilization of hematopoietic progenitor cells in healthy volunteers by AMD 3100, a CXCR4 antagonist. Blood2003;102:2728–30. DOI 10.1182/blood-2003-02-0663.
18.
. BroxmeyerHEOrschellCMClappDWRapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med2005;201:1307–18. DOI 10.1084/jem.20041385.
19.
. FruehaufSSeegerTMaierPThe CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol2006;34:1052–9.
20.
. ReddyGKCrawfordJJainVK.The role of plerixafor (AMD3100) in mobilizing hematopoietic progenitor cells in patients with hematologic malignancies. Support Cancer Ther2006;3:73–6.
21.
. FlomenbergNDevineSMDipersioJFThe use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood2005;106:1867–74. DOI 10.1182/blood-2005-02-0468.
22.
. LilesWCRodgerEBroxmeyerHEAugmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion2005;45:295–300.
23.
. HatseSPrincenKBridgerGDe ClercqEScholsD.Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett2002;527:255–62.
24.
. MatthysPHatseSVermeireKAMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol2001;167:4686–92.
25.
. FrickerSPAnastassovVCoxJCharacterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol2006;72:588–96.
26.
. LukacsNWBerlinAScholsDSkerljRTBridgerGJ.AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am J Pathol2002;160:1353–60.
27.
. TanYLiYXiaoJA novel CXCR4 antagonist derived from human SDF-1beta enhances angiogenesis in ischaemic mice. Cardiovasc Res2009;82:513–21.
28.
. GazittYFreytesCOAkayCBadelKCalandraG.Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients. Stem Cells Dev2007;16:657–66. DOI 10.1089/scd.2006.0087.
29.
. BurgerJAPeledA.CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia2009;23:43–52. DOI 10.1038/Leu.2008.299.
30.
. DevineSMVijRRettigMRapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood2008;112:990–8. DOI 10.1182/blood-2007-12-130179.
31.
. MacFarlandRStewardDCashenAPharmacokinetics of AMD3100 in patients with haematologic malignancies. Bone Marrow Transplant2007;39(suppl 1):S132.
32.
. MacFarlandREwesuedoRBBadelKCalandraG.Pharmacokinetics of plerixafor (AMD3100) in volunteers with renal impairment [49th ASH Annual Meeting abstract]. Blood2007;110:2878.
33.
. MacFarlandRScarboroughRBeckerSPharmacokinetics of AMD3100 in volunteers with renal impairment. Bone Marrow Transplant2007;39(suppl 1):S155.
34.
. MacFarlandRHardMLScarboroughRBadelKCalandraG.A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biol Blood Marrow Transplant. Epub10 Sep2009. DOI 10.1016/j.bbmt.2009.09.003.
35.
. DarAKalinkovichANetzerNAMD3100 signals via the nervous system, inducing release to the circulation of bone marrow SDF-1, which is crucial for progenitor cell mobilization [48th ASH Annual Meeting abstract]. Blood2006;108:1315.
36.
. MartinCBridgerGJRankinSM.Structural analogues of AMD3100 mobilise haematopoietic progenitor cells from bone marrow in vivo according to their ability to inhibit CXCL12 binding to CXCR4 in vitro. Br J Haematol2006;34:326–9. DOI 10.1111/j.1365-2141.2006.06181.x.
37.
. PulliamACHobsonMJCicconeSLAMD3100 synergizes with G-CSF to mobilize repopulating stem cells in Fanconi anemia knockout mice. Exp Hematol2008;36:1084–90. DOI 10.1016/j.exphem.2008.03.016.
38.
. HessDABondeJCraftTCHuman progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor. Biol Blood Marrow Transplant2007;13:398–411.
39.
. StiffPMicallefIMcCarthyPTreatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant2009;15:249–56. DOI 10.1016/j.bbmt.2008.11.028.
40.
. DonahueREJinPBonifacinoACAMD3100 and granulocyte colony stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and micro RNA expression [50th ASH Annual Meeting abstract]. Blood2008;112:1385.
41.
. FruehaufSSeegerTDillmannFThe CXCR4 antagonist AMD3100 mobilizes a more primitive subset of CD34+ cells than G-CSF. Onkologie2005;28(suppl 3):145.
42.
. DiPersioJFMicallefIStiffPJA Phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (plerixafor)+G-CSF vs placebo+G-CSF in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation [49th ASH Annual Meeting abstract]. Blood2007;110:601.
43.
. DiPersioJFMicallefIStiffPJMonths report from the Phase 3 study of plerixafor+G-CSF vs placebo+G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL [50th ASH Annual Meeting abstract]. Blood2008;112:1136.
44.
. DiPersioJFMicallefINStiffPJPhase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol2009;27:4767–73.
45.
. DiPersioJFStadtmauerEANademaneeAPA Phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (plerixafor)+G-CSF vs G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation [49th ASH Annual Meeting abstract]. Blood2007;110:445.
46.
. DiPersioJFStadtmauerEANademaneeAP12 Months report from a Phase 3 study of plerixafor + G-CSF vs placebo + G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma [50th ASH Annual Meeting abstract]. Blood2008;112:3312.
47.
. DiPersioJFStadtmauerEANademaneeAPlerixafor and G-CSF versus placebo to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood2009;113:5720–6. DOI 10.1182/blood-2008-08-174946.
48.
. StiffPJMicallefINademaneeAPTransplanted CD34+ cell dose is associated with long-term platelet count following autologous hematopoietic stem cell transplant in patients with non-Hodgkin's lymphoma and multiple myeloma [50th ASH Annual Meeting abstract]. Blood2008;112:2175.
49.
. TricotGCottler-FoxMHCalandraG.Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant. Epub22 Jun2009. DOI 10.1038/bmt.2009.130.
